🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The NCTN, albeit imperfect, serves a critical role in advancing cancer care by: 1)Conducting pragmatic trials pharma/industry would never sponsor 2)Enrolling across a diverse network (>3K sites) representative of a “real world” population Great editorial Ted Hong Thomas George, MD, FACP, FASCO👏

x.com/i/article/1931…

🎙Nathan A. Pennell MD, PhD, FASCO of Cleveland Clinic and Dr. Cheryl Czerlanis of UW Health | Carbone Cancer Center discuss strategies to increase lung cancer screenings and leverage AI for early detection on the ASCO Education #BytheBook Podcast. Listen now: brnw.ch/21wTirK

FDA to Issue New Commissioner’s National Priority Vouchers to Companies Supporting U.S. National Interests. $XBI Drug developers may redeem the new voucher that shortens the review time from apprx 10-12 months to 1-2 months fda.gov/news-events/pr…

The #ASCOEdBook 2025 collection is now complete. Thank you to editors Nathan A. Pennell MD, PhD, FASCO, @hoperug0, and Pedro C Barata, MD MSc FACP and all 2025 contributors 👏 👏 Check out the full edition: bit.ly/44bvEkk

🔥📣The 2025 #ASCOEdBook collection from ASCO #ASCO25 is now complete & fully available (for free). ✅It’s a great resource with very EDUCATIONAL peer-reviewed articles by great experts. Outstanding job by editors & authors.👏 Link to full edition👇🏻 bit.ly/44bvEkk

In our latest FDA Direct conversation, we dive into recent policy changes: • Updates on the Commissioner’s National Priority Voucher program • Review of certain clinical trials involving foreign labs • Dr. Marty Makary insights from the BIO Conference

Review on next generation immunotherapies in NSCLC doi.org/10.1038/s41571… #LCSM d.planchard Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ Benjamin Besse Sanjay Popat Giannis Mountzios Fred R. Hirsch Suresh S. Ramalingam, MD, FASCO Christine Lovly, MD, PhD, FASCO Hossein Borghaei, DO Joshua Reuss Chul Kim Biagio Ricciuti, MD, PhD Aakash Desai, MD, MPH, FASCO Eric K. Singhi, MD

Datopotamab deruxtecan (DatoDXd - Trop2 ADC) now FDA Oncology approved off #TROPIONLung01 & 05 for previously treated mEGFR NSCLC - ORR of 42.7%, mDoR 7.0 mos - mPFS: 5.8 mos and mOS 15.6 mos - AEs: Nausea, stomatitis, and ILD #lcsm #OncTwitter U.S. FDA

“Who decides who decides?” An editorial based on Rebecca Campbell & Laura Bukavina’s work in which we explore how altmetrics & digital clout are shaped by systemic bias. Honored to cowrite this with Stephanie Graff, MD, FACP, FASCO 🔗 ascopubs.org/doi/10.1200/OP… #MedTwitter #WomenInMedicine

🎙️ Vamsi Velcheti, MD MBA FASCO of Mayo Clinic and Nathan A. Pennell MD, PhD, FASCO of Cleveland Clinic highlight key abstracts in SCLC and NSCLC that stood out at #ASCO25 on the latest episode of the #ASCODailyNews Podcast: bit.ly/44eLPgB

"A generation of trainees are encountering a system in which discontinuity is the norm and the associated harms remain hidden — or worse, become routine and acceptable. We risk a tipping point of normalized deviance where we can no longer see how our actions — in this case,

🚨 #Lungcancer survival has more than doubled. New real-world data from France shows 3-year survival for lung adenocarcinoma rose from 16.3% (2000) to 38.6% (2020) driven by earlier diagnosis & targeted treatment. This is what progress looks like. But it must reach everyone who

Real-World Adherence Patterns of Comprehensive Genomic Profiling to Biomarker Recommended Therapies in Pts w/ Advanced Non–Small Cell Lung Cancer [Jun 30, 2025] Ben-Shachar et al. Tempus JCO Precision Oncology ascopubs.org/doi/10.1200/OP… #lcsm #PrecisionMedicine

The American people should have immediate free access to the science that we so generously fund through the NIH. Starting today, we do.

Sunvozertinib (oral EGFR inhibitor, 200mg Qd) now U.S. FDA approved based off PhII WU-KONG1 in previously treated Exon20ins mNSCLC: - Confirmed 44.9% ORR w/ 9mos DoR: 57% - ≥Gr 3: Diarrhea (17%), CPK levels (11%), and anemia (3.6%) #OncTwitter #MedTwitter

I ❤️ the intersection of medicine and the humanities. These are the articles that remind us why we do what we do. Checkout the Art of Oncology Narrative Medicine Contest ⁦Journal of Clinical Oncology⁩ ⁦JCO Global Oncology⁩ ascopubs.org/jco/art-oncolo…

nytimes.com/2025/07/08/mag… 🤦‍♂️